AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39028918 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy, specific dosage and duration not available
Number of subjects: 0
Study 39028918 — intervention group
Group type: COMPARATOR
Intervention: Placebo control, specific dosage and duration not available
Number of subjects: 0
Study 39028923 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) trastuzumab/pertuzumab (HP)
Number of subjects: 22
Study 39028923 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) trastuzumab/pertuzumab (HP)
Number of subjects: 22
Study 39028926 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Ifosfamide, and Cisplatin (TIP)
Number of subjects: 104
Study 39028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib and Blinatumomab
Number of subjects: 0
Study 39028931 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib for a median of 56 days before surgical resection
Number of subjects: 27
Study 39028996 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch monitoring for arrhythmias post-TAVR
Number of subjects: 188
Study 39029241 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning AI system for serial digital breast tomosynthesis (DBT) images
Number of subjects: 149
Study 39029295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib 960 mg once daily
Number of subjects: 209
Study 39029295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib 240 mg once daily
Number of subjects: 209
Study 39029481 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA15 (135 μg or 180 μg)
Number of subjects: 58
Study 39029481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 39029481 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA15
Number of subjects: 58
Study 39029483 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus radiosurgery (25 Gy external-beam photons)
Number of subjects: 125
Study 39029568 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5mg/day
Number of subjects: 84
Study 39029568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 39029639 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity professional development intervention for preschool staff
Number of subjects: 1265
Study 39029639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1265
Study 39029733 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perception conversation (IPC)
Number of subjects: 103
Study 39029733 — intervention group
Group type: COMPARATOR
Intervention: Research participation conversation (RPC)
Number of subjects: 103
Study 39029784 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall suction drainage
Number of subjects: 221
Study 39029784 — intervention group
Group type: COMPARATOR
Intervention: Gravity drainage
Number of subjects: 221
Study 39029876 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (FLAURA)
Number of subjects: 146
Study 39029876 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR-TKIs (FLAURA)
Number of subjects: 146
Study 39029876 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (AURA3)
Number of subjects: 146
Study 39029876 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (AURA3)
Number of subjects: 146
Study 39030060 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV239 (recombinant HEV vaccine)
Number of subjects: 19460
Study 39030060 — intervention group
Group type: COMPARATOR
Intervention: Hepa-B (control vaccine)
Number of subjects: 19460
Study 39030060 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV239
Number of subjects: 19460
Study 39030060 — intervention group
Group type: COMPARATOR
Intervention: Hepa-B
Number of subjects: 19460
Study 39030061 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV239
Number of subjects: 5011
Study 39030061 — intervention group
Group type: COMPARATOR
Intervention: Hepa-B (control)
Number of subjects: 5011
Study 39030063 — intervention group
Group type: EXPERIMENTAL
Intervention: Group medical visits
Number of subjects: 2890
Study 39030063 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfinance
Number of subjects: 2890
Study 39030063 — intervention group
Group type: EXPERIMENTAL
Intervention: GMV-MF (Group medical visits + Microfinance)
Number of subjects: 2890
Study 39030063 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2890
Study 39030062 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance testing (GRT) with expert recommendation
Number of subjects: 284
Study 39030062 — intervention group
Group type: COMPARATOR
Intervention: Usual care (repeat viral-load testing and empirical onward treatment)
Number of subjects: 284
Study 39030183 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, lenalidomide, and dexamethasone (Dara-Rd)
Number of subjects: 32
Study 39030450 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent chromium (Cr III)
Number of subjects: 0
Study 39030450 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib
Number of subjects: 0
Study 39030560 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable Ultrasonic Shears manufactured by Reach Surgical, Inc.
Number of subjects: 144
Study 39030560 — intervention group
Group type: COMPARATOR
Intervention: Harmonic Ace + 7, 5 mm Diameter Shears with Advanced Hemostasis
Number of subjects: 144
Study 39030622 — intervention group
Group type: EXPERIMENTAL
Intervention: Email recruitment
Number of subjects: 27319
Study 39030622 — intervention group
Group type: COMPARATOR
Intervention: Postal mail recruitment
Number of subjects: 27319
Study 39030750 — intervention group
Group type: EXPERIMENTAL
Intervention: #EnufSnuff.TXT intervention
Number of subjects: 532
Study 39030750 — intervention group
Group type: COMPARATOR
Intervention: Enough Snuff intervention
Number of subjects: 532
Study 39030919 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg daily for 10 weeks
Number of subjects: 0
Study 39031189 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes (GDM)
Number of subjects: 1843
Study 39031189 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 1843
Study 39031232 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurement (SpHb®; Masimo)
Number of subjects: 62
Study 39031232 — intervention group
Group type: COMPARATOR
Intervention: Laboratory hemoglobin (labHb)
Number of subjects: 62
Study 39031276 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg (UPA15)
Number of subjects: 303
Study 39031339 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control exercise combined with synchronized breathing techniques
Number of subjects: 30
Study 39031339 — intervention group
Group type: COMPARATOR
Intervention: Identical movement control exercises without synchronized breathing
Number of subjects: 30
Study 39031356 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCVD risk estimator
Number of subjects: 253
Study 39031356 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc
Number of subjects: 253
Study 39031449 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFID-PTP (two 2-hour individual treatment sessions with an optional booster session at 4-week follow-up)
Number of subjects: 30
Study 39031449 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFID-PTP
Number of subjects: 30
Study 39031824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg daily) plus pembrolizumab (200 mg every 3 weeks; up to 35 cycles)
Number of subjects: 31
Study 39031963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (350 mg IV every 3 weeks for 5 cycles of 9 weeks/cycle, then 4 cycles of 12 weeks/cycle)
Number of subjects: 0
Study 39031963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 0
Study 39032151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer Falls in MS programme (theory-based online fall prevention self-management programme)
Number of subjects: 4
Study 39032151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer Falls in MS programme (Beta version pretest)
Number of subjects: 4
Study 39032243 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided model with individual-calibrated or population-assigned parameters
Number of subjects: 15
Study 39032243 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal catheter placements identified using the image-guided model
Number of subjects: 15
Study 39032557 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Fr Glidesheath Slender (GSS)
Number of subjects: 620
Study 39032557 — intervention group
Group type: COMPARATOR
Intervention: 6-Fr Conventional Sheath (CS)
Number of subjects: 620
Study 39032770 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth in September and October (preharvest months)
Number of subjects: 100
Study 39032787 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet (PBD) with high potassium content delivered as a weekly food basket while continuing sodium zirconium cyclosilicate (SZC) for 3 weeks
Number of subjects: 26
Study 39032787 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein low-potassium diet plus sodium zirconium cyclosilicate (SZC) for 3 weeks
Number of subjects: 26
Study 39032815 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAP
Number of subjects: 240
Study 39032815 — intervention group
Group type: EXPERIMENTAL
Intervention: BRITE
Number of subjects: 240
Study 39032815 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAP+BRITE
Number of subjects: 240
Study 39032815 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 240
Study 39032927 — intervention group
Group type: EXPERIMENTAL
Intervention: Institution-based adapted physical activity programme
Number of subjects: 40
Study 39032927 — intervention group
Group type: COMPARATOR
Intervention: Home-based self-management programme
Number of subjects: 40
Study 39032926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently dosed relacorilant in combination with nab-paclitaxel
Number of subjects: 0
Study 39032926 — intervention group
Group type: COMPARATOR
Intervention: Nab-paclitaxel monotherapy
Number of subjects: 0
Study 39032929 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 306
Study 39032929 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (SA)
Number of subjects: 306
Study 39033046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual delayed-release esomeprazole (10 mg)
Number of subjects: 0
Study 39033046 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (20 mg)
Number of subjects: 0
Study 39033111 — intervention group
Group type: EXPERIMENTAL
Intervention: IY-ASLD® intervention, delivered online by clinical psychologists and child and adolescent psychiatrists.
Number of subjects: 68
Study 39033111 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 68
Study 39033125 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week plantar intrinsic foot muscle strengthening training, performed 5 times a week for approximately 20 minutes per session, supervised once a week with gradually increasing intensity.
Number of subjects: 0
Study 39033125 — intervention group
Group type: COMPARATOR
Intervention: Control group limited to keeping a diary of physical activities, fall incidents, and movement-related discomfort.
Number of subjects: 0
Study 39033201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal antiseptic solution containing povidone-iodine (n=25)
Number of subjects: 50
Study 39033201 — intervention group
Group type: COMPARATOR
Intervention: Control solution (n=25)
Number of subjects: 50
Study 39033240 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression in tumor cells (TC) and immune cells (IC)
Number of subjects: 248
Study 39033240 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression in tumor cells (TC)
Number of subjects: 248
Study 39033240 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression in immune cells (IC)
Number of subjects: 248
Study 39033240 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ T cells
Number of subjects: 248
Study 39033240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor mutation burden (TMB)
Number of subjects: 248
Study 39033240 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PD-L1 expression with CD8+ T cells
Number of subjects: 248
Study 39033266 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergen-specific substitutive diet (FASSD) as a 6-month dietary treatment option.
Number of subjects: 0
Study 39033266 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial strategy for ARFS management.
Number of subjects: 0
Study 39033273 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted intervention (n=115)
Number of subjects: 231
Study 39033273 — intervention group
Group type: COMPARATOR
Intervention: Participant-only intervention (n=116)
Number of subjects: 231
Study 39033325 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) screening
Number of subjects: 7000
Study 39033364 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial fundal incision (EFI) during hysteroscopy
Number of subjects: 124
Study 39033364 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopy only (no intervention)
Number of subjects: 124
Study 39033367 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing with 2 ml of clear follicular fluid from 2 to 3 dominant follicles after oocyte retrieval
Number of subjects: 140
Study 39033367 — intervention group
Group type: COMPARATOR
Intervention: Control group (uterine cavity catheterisation only)
Number of subjects: 140
Study 39033370 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg triptorelin (Decapeptyl)
Number of subjects: 70
Study 39033370 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of GnRH agonist
Number of subjects: 70
Study 39033369 — intervention group
Group type: EXPERIMENTAL
Intervention: DLBS3233 100-mg daily
Number of subjects: 124
Study 39033369 — intervention group
Group type: COMPARATOR
Intervention: Metformin-XR 750 mg twice daily
Number of subjects: 124
Study 39033475 — intervention group
Group type: EXPERIMENTAL
Intervention: External neuromuscular electrical stimulation (NMES) + lifestyle advice
Number of subjects: 30
Study 39033475 — intervention group
Group type: COMPARATOR
Intervention: Sham NMES + lifestyle advice
Number of subjects: 30
Study 39033484 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D mesh repair
Number of subjects: 86
Study 39033484 — intervention group
Group type: COMPARATOR
Intervention: Sugarbaker repair
Number of subjects: 86
Study 39033591 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA
Number of subjects: 139
Study 39033591 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 139
Study 39033591 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX
Number of subjects: 139
Study 39033692 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 114
Study 39033766 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream 20 mg/g
Number of subjects: 487
Study 39033766 — intervention group
Group type: COMPARATOR
Intervention: Cream vehicle
Number of subjects: 487
Study 39033767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg daily for 2 years
Number of subjects: 61
Study 39033767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 39033770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib 200 mg orally once a day in 28-day cycles
Number of subjects: 82
Study 39033770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib 150 mg orally once a day (1 patient)
Number of subjects: 82
Study 39033774 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe-assisted colonoscopy (GI Genius)
Number of subjects: 430
Study 39033774 — intervention group
Group type: COMPARATOR
Intervention: WLE (white light endoscopy)
Number of subjects: 430
Study 39033924 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 2823
Study 39033924 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 2823
Study 39033994 — intervention group
Group type: EXPERIMENTAL
Intervention: C-QIP intervention consisting of electronic health records, trained nonphysician health workers, text-message reminders, patient education materials, and quarterly audit and feedback reports.
Number of subjects: 410
Study 39033994 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 410
Study 39034414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexfin (non-invasive ABP measurement)
Number of subjects: 50
Study 39034414 — intervention group
Group type: COMPARATOR
Intervention: Arterial catheter (invasive ABP measurement)
Number of subjects: 50
Study 39034428 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial Ablation (AA)
Number of subjects: 98
Study 39034428 — intervention group
Group type: COMPARATOR
Intervention: Terminal Interruption of the Reflux Source (TIRS)
Number of subjects: 98
Study 39034443 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 65
Study 39034443 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 65
Study 39034493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lethally irradiated lymphoma cells admixed with GM-K562 cells; maximum of 6 vaccines administered
Number of subjects: 0
Study 39034924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve-in-valve replacement using a balloon-expandable transcatheter heart valve (SAPIEN 3, Edwards Lifesciences) via transeptal approach.
Number of subjects: 50
Study 39034968 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus lorlatinib (100 mg once daily)
Number of subjects: 0
Study 39034968 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus crizotinib (250 mg twice daily)
Number of subjects: 0
Study 39035044 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa (AVA)
Number of subjects: 100
Study 39035044 — intervention group
Group type: COMPARATOR
Intervention: alglucosidase alfa (ALG)
Number of subjects: 100
Study 39035147 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel applied daily internally and externally to the genital area for approximately 6 months (short-term) and optionally up to 2 years (long-term)
Number of subjects: 52
Study 39035569 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral obesity phenotype
Number of subjects: 187
Study 39035569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic obesity phenotype
Number of subjects: 187
Study 39035569 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosteatotic obesity phenotype
Number of subjects: 187
Study 39035569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatosteatotic obesity phenotype
Number of subjects: 187
Study 39035569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity phenotype
Number of subjects: 187
Study 39035614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation-directed optimal blood pressure management
Number of subjects: 51
Study 39035614 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 51
Study 39035685 — intervention group
Group type: EXPERIMENTAL
Intervention: Single acupoint (Zhongwan, CV-12)
Number of subjects: 99
Study 39035685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination acupoints (Zhongwan, CV-12 and Zusanli, ST-36)
Number of subjects: 99
Study 39035685 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 99
Study 39035725 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/S-1 (TS)
Number of subjects: 111
Study 39035725 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/capecitabine (TX)
Number of subjects: 111
Study 39035727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 168
Study 39035732 — intervention group
Group type: EXPERIMENTAL
Intervention: YWJP
Number of subjects: 212
Study 39035732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 39035774 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCVD
Number of subjects: 627
Study 39035774 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 627
Study 39035788 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR HDM-SLIT tablet
Number of subjects: 3699
Study 39035788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3699
Study 39036069 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-1701 (HER2-targeting eribulin-containing ADC)
Number of subjects: 0
Study 39036069 — intervention group
Group type: COMPARATOR
Intervention: HER2-targeting ADCs with DM1 and Dxd payload
Number of subjects: 0
Study 39036300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 420
Study 39036300 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (control)
Number of subjects: 420
Study 39036423 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to increase clinician-initiated SICs
Number of subjects: 1187
Study 39036423 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (controls)
Number of subjects: 1187
Study 39036772 — intervention group
Group type: EXPERIMENTAL
Intervention: FASST app (intervention group, n = 20)
Number of subjects: 30
Study 39036772 — intervention group
Group type: COMPARATOR
Intervention: Limited app with basic FASST interface (control group, n = 10)
Number of subjects: 30
Study 39036772 — intervention group
Group type: EXPERIMENTAL
Intervention: FASST app (intervention group)
Number of subjects: 30
Study 39036772 — intervention group
Group type: COMPARATOR
Intervention: Limited app with basic FASST interface (control group)
Number of subjects: 30
Study 39036871 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON Gold In-Tube (QGIT)
Number of subjects: 2232
Study 39036871 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin Skin Test (Control)
Number of subjects: 2232
Study 39036981 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2482 450 mg
Number of subjects: 2977
Study 39036981 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2482 1200 mg
Number of subjects: 2977
Study 39036981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2977